Molecular Medicine Reports · 2020 · 13 citations · 27 references
MedicinePharmacologyToxicologyChemotherapyHearing ScienceOtologyCochlear FunctionCochlear NeurobiologyCochlear NeuroscienceHearing ImpairmentHearing LossOtotoxicityCell Viability AssaysChemotherapy-induced OtotoxicityChemotherapy-related OtotoxicityCisplatin OtotoxicityCochlear ToxicityOtotoxicity MechanismsOtotoxicity PathophysiologyPharmacologic Ototoxicity
Sensorineural hearing loss is prevalent in patients receiving cisplatin therapy. Tetramethylpyrazine (Tet) and tanshinone IIA (Tan IIA) have protective roles against hearing impairment or ototoxicity. The present study aimed to investigate the molecular mechanisms underlying cisplatin‑induced ototoxicity and the protective effect of Tet and Tan IIA against it. House Ear Institute‑Organ of Corti 1 auditory cells were treated with titrating doses of Tan IIA, Tet, and cisplatin. In a cell viability assay, cisplatin, Tan IIA and Tet had IC50 values of 42.89 µM, 151.80 and 1.04x103 mg/l, respectively. Tan IIA augmented cisplatin‑induced cytotoxicity. However, Tet concentrations <75 mg/l attenuated cisplatin‑induced cytotoxicity and apoptosis. Moreover, RNA sequencing analysis was carried out on auditory cells treated for 30 h with 30 µM cisplatin alone for 48 h or combined with 37.5 mg/l Tet for 30 h. Differentially expressed genes (DEGs) induced in these conditions were identified and examined using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis. Cisplatin increased the expression of genes related to the p53 and FoxO pathways, such as Fas, p21/CDKN1A, and Bcl‑2 binding component 3, but decreased the expression of insulin‑like growth factor 1 (IGF1), as well as genes in the histone (Hist)1 and Hist2 clusters. Treatment with Tet downregulated FOXO3 and Bcl‑2 binding component 3, and increased the expression of IGF1. Moreover, Tet upregulated genes associated with Wnt signaling, but not p53‑related genes. Thus, the otoprotective properties of Tet might be mediated by activation of Wnt and IGF1 signaling, and inhibition of FoxO signaling.
27
Cisplatin is retained in the cochlea indefinitely following chemotherapy
Andrew Breglio, Aaron E. Rusheen, Eric Shide et al. · Nature Communications · 2017 · 406 citations · Full text
Wnt activation protects against neomycin-induced hair cell damage in the mouse cochlea
L Liu, Yuhong Chen, Jieyu Qi et al. · Cell Death and Disease · 2016 · 128 citations · Full text
Hearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood Cancer
Johnnie K. Bass, Chia‐Ho Hua, Jie Huang et al. · Journal of Clinical Oncology · 2016 · 124 citations
Medicine, Oncology, Otolaryngology +17